Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
RHHVF - ROCHE HOLDINGS AG
Market Cap 252.34B P/E 17.22 EPS this Y - Ern Qtrly Grth 12.10%
Income 11.5B Forward P/E 14.36 EPS next Y - 50D Avg Chg -1.00%
Sales 60.44B PEG - EPS past 5Y -0.29% 200D Avg Chg -1.00%
Dividend 3.00% Price/Book 8.82 EPS next 5Y 5.48% 52W High Chg -12.00%
Recommedations 1.00 Quick Ratio 0.94 Shares Outstanding 690.55M 52W Low Chg 13.00%
Insider Own - ROA 12.44% Shares Float 727.48M Beta 0.15
Inst Own 38.26% ROE 37.86% Shares Shorted/Prior -/- Price 308.83
Gross Margin 74.20% Profit Margin 19.02% Avg. Volume 8,359 Target Price -
Oper. Margin 23.90% Earnings Date - Volume 13,680 Change 1.32%
Healthcare | Drug Manufacturers - General | Switzerland
About ROCHE HOLDINGS AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

ROCHE HOLDINGS AG News
04/24/24 Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
04/24/24 UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
04/24/24 [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
04/19/24 Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
04/19/24 Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
04/19/24 Roche wins FDA OK for Alecensa in early lung cancer
04/19/24 FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
04/18/24 FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
04/17/24 Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
04/17/24 Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
04/15/24 Adaptimmune (ADAP) Down on End of Collaboration With Roche
04/15/24 Roche reports survival data for new dual-acting lymphoma drug
04/15/24 Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
04/15/24 Roche to distribute Prenosis’ AI sepsis detection tool in US
04/15/24 Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
04/15/24 [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
04/12/24 Roche scores FDA breakthrough status for Alzheimer’s blood test
04/12/24 Roche, Adaptimmune part ways on cell therapy research
04/11/24 Why Roche Holdings Stock Popped Today
04/11/24 ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study